达雷妥尤单抗难治性多发性骨髓瘤患者在其他治疗一段时间后再次接受CD38抗体治疗
本研究通过离体敏感性检测评估达雷妥尤单抗暴露后停药患者对CD38抗体的敏感性。停药超过1年的患者骨髓瘤细胞敏感性高于停药不足1年者,但仍低于未暴露患者。离体敏感性可预测后续临床反应,而CD38过表达不能预测。临床再治疗获益不足6个月,1例达雷妥尤单抗暴露但非难治患者获得持续13个月的完全缓解。
要点
- 停药超过1年的患者骨髓瘤细胞对CD38抗体敏感性高于停药不足1年者,但仍低于未暴露患者。
- 离体敏感性可预测后续临床反应,而CD38过表达不能预测。
- CD38抗体再治疗临床获益不足6个月,1例暴露非难治患者完全缓解持续13个月。
核心结论
- 等待1年后再挑战CD38抗体可获得短暂疗效,但该方法可能最适合作为嵌合抗原受体T细胞治疗的桥接或后续治疗。
研究设计与样本
- 研究采用离体敏感性检测,样本来自曾暴露于达雷妥尤单抗并停药长达53个月的患者。
主要发现
- 停药超过1年的患者骨髓瘤细胞对CD38抗体敏感性高于停药不足1年者,但仍低于未暴露患者。
- 骨髓瘤细胞CD38表达逐渐恢复,但仍未达到未暴露患者水平。
- 低CD38表达仅能解释45%的达雷妥尤单抗耐药病例。
- 离体敏感性可预测后续临床反应,而CD38过表达不能预测。
- 临床再治疗患者获益不足6个月,1例达雷妥尤单抗暴露但非难治患者获得持续13个月的完全缓解。
临床怎么用
- 作者认为等待1年后再挑战CD38抗体可获得短暂疗效,但该方法可能最适合作为嵌合抗原受体T细胞治疗的桥接或后续治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal antibodies targeting CD38 are important for treatment of both newly diagnosed and relapsed multiple myeloma (MM). Daratumumab and isatuximab are anti-CD38 antibodies with the US Food and Drugs Administration approval in multiple different combinations. Despite good initial efficacy, patients inevitably develop drug resistance. Whether patients can be effectively re-treated with these antibodies in subsequent lines of therapy is unclear. Thus far, studies have mostly been limited to clinical retrospectives with short washout periods. To answer whether patients regain sensitivity after longer washouts, we used ex vivo sensitivity testing to isolate the anti-CD38 antibody-specific cytotoxicity in samples obtained from patients who had been exposed to and then off daratumumab for up to 53 months. MM cells from patients who had been off daratumumab for >1 year showed greater sensitivity than those with <1 year, although they still were less sensitive than those who were daratumumab naïve. CD38 expression on MM cells gradually recovered, although, again, not to the level of anti-CD38 antibody-naïve patients. Interestingly, low MM CD38 explained only 45% of cases identified to have daratumumab resistance. With clinical follow-up, we found ex vivo sensitivity predicted subsequent clinical response but CD38 overexpression did not. Patients clinically re-treated with anti-CD38 antibodies had <6 months of clinical benefit, but 1 patient who was daratumumab exposed but not refractory achieved complete response lasting 13 months. We conclude that transient efficacy can be achieved by waiting 1 year before CD38 antibody rechallenge, but this approach may be best used as a bridge to, or after, chimeric antigen receptor T-cell therapy.
引用
- Perez de Acha O, Reiman L, Jayabalan DS, et al. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies. Blood Adv. 2023. PMID: 37648670. doi:10.1182/bloodadvances.2023010162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。